drugset / Trial / NCT02603406

Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits

NCT02603406

RandomizedParallel-groupDouble-blindTreatment

Summary

Neovascularization Induced by Mechanical Barrier disrUption and Systemic erythropoietin in patients with cerebral perfusion deficits (NIMBUS trial)

Timeline

Start
2016-07-15
Primary completion
2019-07-16
Completion
2019-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 33000 iu Intravenous

Indications